The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.